Opioids

Shares of companies embroiled in the U.S. opioid crisis were trading sharply higher Wednesday following a Tuesday Wall Street Journal report that said three opioid drug distributors are in talks with state and local governments regarding a settlement agreement. Distributors Discuss Deal...

Johnson & Johnson (NYSE: JNJ) announced a $20.4-million agreement Wednesday with the Ohio counties of Cuyahoga and Summit to settle an opioid lawsuit with the state, removing the company from federal multidistrict litigation. The Analysts Credit Suisse analyst Matt Miksic reiterated an...

OxyContin maker Purdue Pharma filed for Chapter 11 bankruptcy protection Sunday in a widely expected move. Why The Bankruptcy Filing Each day, over 130 people in the U.S. die from opioid overdoses, according to the National Institute on Drug Abuse. Purdue is facing a slew of lawsuits filed...

Mallinckrodt PLC (NYSE: MNK) shares have been on an extended downtrend since the middle of 2015. From over $130 in early 2015, the stock is now barely above $1. Much of the downside is attributable to allegations regarding opioid addiction and opioid overdose deaths that implicate not only...

Johnson & Johnson (NYSE: JNJ) and its prescription drugs unit are responsible for helping fuel Oklahoma's opioid drug problem, a judge ruled Monday, making the conglomerate the first to be held to blame by a court for the epidemic. Judge Thad Balkman ordered the company to pay $572.1...

Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers. The Analyst Morgan Stanley analyst David Risinger made the following changes to his pharma stock coverage: Endo...

Insys Therapeutics Inc (NASDAQ: INSY) Chairman Steven Meyer and board member Pierre Lapalme will resign "upon the execution of the agreements relating to the settlement with the U.S. Department of Justice," according to Reuters. Insys Therapeutics has agreed to pay $225 million and plead...

With Johnson & Johnson (NYSE: JNJ) facing off against the state of Oklahoma this week over its potential responsibility for the opioid crisis in that state, BMO Capital Markets issued a report Thursday on the company's thinking as it heads to court. The Analyst Joanne Wuensch...

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares have been under pressure since mid-May, when it was accused along with other generic companies for inflating the prices of generic drugs. The Israeli drugmaker announced an $85-million settlement agreement Tuesday with the state of...

Opioid drugmaker Insys Therapeutics Inc (NASDAQ: INSY) may soon go bust, the company suggested in the first-quarter earnings report it released Friday after the close. Following Insys' fourth-quarter print in March, analysts were largely bullish on the company, premising their optimism on...

The Street will gain access this week to an investment in the only opioid marketed in the U.S. and Europe without being classified as a controlled substance. The IPO Trevi Therapeutics, Inc. will issue nearly 4.7 million shares on the Nasdaq under ticker TRVI, according to the firm’s S-1...

Insys Therapeutics (NASDAQ: INSY) shares were crashing Wednesday after the company disclosed in its annual filing that the auditor's opinion on its audited financial statements include a paragraph stating concerns about the company's ability to continue. The stock was halted on a...

Privately held Purdue Pharma, which has the dubious distinction of being a party to the opioid crisis in the U.S., is reportedly considering filing for Chapter 11 bankruptcy as it faces a slew of lawsuits tied to the opioid OxyContin, according to reports from Reuters and the Wall Street...

You can’t treat the opioid crisis without treating the underlying issue: chronic pain. How states like Pennsylvania solve both will determine how long the opioid crisis will persist in communities across the country. 130. That’s the average number of Americans who die from opioid...

Amid the lengthy shutdown crippling federal services nationwide, President Donald Trump doubled down on his commitment to construct a southern border wall in his Tuesday address. What Trump Said Trump attributed domestic economic concerns to southern border violations. “All Americans are hurt...